BIONANOTEXNOLOGIYADAN FOYDALANIB YURAK QON-TOMIR KASALLIKLARINI OLDINI OLISH USULLARI
Article Sidebar
Main Article Content
Abstract:
Hoirgi davrda turli yurak kasalliklari tufayli insonlarda yurak yetishmovchiligi kundan-kunga oshmoqda. Bu esa nafaqat tibbiyot balki biotexnologiya oldidagi muammolardan biridir. Hozirgi vaqtda organ transplantatsiyasi va yordamchi asboblari bu bemorlar uchun yagona samarali davolash usuli bo'lib qolmoqda. Oltin nanozarralar va uglerod nanotubalari kabi nanomateriallar yurak to'qimasini muhandislik yondashuvlari uchun foydali bo'lgan noyob xususiyatlarni taqdim etadi. Xususan, ushbu nanomateriallar to'qimalarning funksionalligini yaxshilash uchun elektr o'tkazuvchanligini, qattiqligini modulyatsiya qilishi mumkin. Bundan tashqari, ular hujayra fenotiplariga ta'sir qilish uchun bioaktiv yuklarni yetkazib berishlari mumkin.
Article Details
How to Cite:
References:
Kostrzewa B, Rybak Z (2013). "[History, present and future of biomaterials used for artificial heart valves]". Polimery W Medycynie. 43 (3): 183–9.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. (September 2017). "2017 ESC/EACTS Guidelines for the management of valvular heart disease". European Heart Journal. 38 (36): 2739–2791.
"Heart Valve Replacement: Which Type Is Best for You?". Health Essentials from Cleveland Clinic. 2018-06-14. Retrieved 2020-08-04.
Muraru D, Anwar AM, Song J (December 2016). "Heart valve disease: tricuspid valve disease". Oxford Medicine Online.
"Surgical aortic heart valves | Edwards Lifesciences". www.edwards.com. Retrieved 2019-07-29.
Medtronic. "Heart Valve Therapies - Surgical Replacement". www.medtronic.com. Retrieved 2019-07-29.
"Surgical Valves | Trifecta GT Valve and Epic Mitral Valve". www.cardiovascular.abbott. Retrieved 2019-07-29.[permanent dead link]
"On-X Heart Valves". CryoLife, Inc. Retrieved 2019-07-29.
"Cardiac | LifeNet Health". www.lifenethealth.org. Retrieved 2019-07-29.
Jump up to: Gott VL, Alejo DE, Cameron DE (December 2003). "Mechanical heart valves: 50 years of evolution". The Annals of Thoracic Surgery. 76 (6): S2230-9.
Jump up to: Pibarot P, Dumesnil JG (February 2009). "Prosthetic heart valves: selection of the optimal prosthesis and long-term management". Circulation. 119 (7): 1034–48.
Goldsmith I, Turpie AG, Lip GY (November 2002). "Valvar heart disease and prosthetic heart valves". BMJ. 325 (7374): 1228–31.
Sun JC, Davidson MJ, Lamy A, Eikelboom JW (August 2009). "Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends". Lancet. 374 (9689): 565–76.
Johansen P (September 2004). "Mechanical heart valve cavitation". Expert Review of Medical Devices. 1 (1): 95–104. .
Namdari M, Eatemadi A (December 2016). "Nanofibrous bioengineered heart valve-Application in paediatric medicine". Biomedicine & Pharmacotherapy. 84: 1179–1188.
Hickey GL, Grant SW, Bridgewater B, Kendall S, Bryan AJ, Kuo J, Dunning J (June 2015). "A comparison of outcomes between bovine pericardial and porcine valves in 38,040 patients in England and Wales over 10 years". European Journal of Cardio-Thoracic Surgery. 47 (6): 1067–74.
https://www.frontiersin.org/articles/10.3389/fbioe.2020.608844/full#h1